The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized trial of thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer (NSCLC): Long-term follow-up of Japan Clinical Oncology Group (JCOG) Study JCOG0301.
 
Shinji Atagi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca Japan (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Junki Mizusawa
No Relationships to Disclose
 
Satoshi Ishikura
No Relationships to Disclose
 
Toshiaki Takahashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly; Ono Pharmaceutical; Pfizer
Research Funding - AstraZeneca Japan (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroaki Okamoto
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
 
Hiroshi Tanaka
Honoraria - AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst)
 
Koichi Goto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Life Technologies; Lilly; Merck Serono; Novartis; Ono Pharmaceutical; Pfizer; Quintiles; SRL Diagnostics; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo
Research Funding - Abbvie; Amgen Astellas BioPharma; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical; OxOnc; Pfizer; Riken Genesis; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
 
Kazuhiko Nakagawa
Honoraria - Astellas Pharma; AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; EPS Holdings; Kyowa Hakko Kirin; Lilly; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Showa Yakuhin Kako; SymBio Pharmaceuticals
Research Funding - AstraZeneca Japan (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Associates Co., Ltd. (Inst); Japan Clinical Research Operations (Inst); Kyowa Hakko Kirin (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); PPD-SNBL (Inst); Quintiles Inc. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Masao Harada
No Relationships to Disclose
 
Yuichiro Takeda
No Relationships to Disclose
 
Naoyuki Nogami
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Yuka Fujita
Honoraria - ARKRAY; Boehringer Ingelheim; Boehringer Ingelheim; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Pfizer; Taiho Pharmaceutical
 
Takashi Kasai
No Relationships to Disclose
 
Kazuma Kishi
Speakers' Bureau - Chugai Pharma
Research Funding - Chugai Pharma (Inst); MSD (Inst)
 
Toshiyuki Sawa
No Relationships to Disclose
 
Koji Takeda
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Lilly; Merck Serono; Ono Pharmaceutical
 
Keisuke Tomii
Honoraria - AstraZeneca; Boehringer Ingelheim
Consulting or Advisory Role - Lilly
 
Miyako Satouchi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Takashi Seto
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Kissei Pharmaceutical; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Roche; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst)
 
Yuichiro Ohe
Stock and Other Ownership Interests - Ono Pharmaceutical (I)
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Lilly Japan; MSD; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly Japan; Novartis; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Kyorin (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
Expert Testimony - AstraZeneca